hotspot -WSS

hotspot

author：explore 2025-09-29 22:52:44 - browse：2

Vertex Pharmaceuticals Inc. building — Craig F. Walker/The Boston Globe

Vertex Pharmaceuticals said Friday that, over a year after receiving the company’s stem-cell therapy, two type 1 diabetes patients no longer need to take insulin injections and saw stark reductions in a biological marker of disease.

The results, presented at the American Diabetes Association conference in San Diego, bolstered experts’ hopes that the treatment could provide a functional cure for some patients. In 2021, Vertex announced dramatic results from the first man to receive the treatment, but researchers cautioned it was just one person, who had only been followed for 90 days.

“The data look as good as they could be,” said Jeanne Loring, a stem cell expert and professor emeritus at Scripps Research not involved in the work, in an email.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： Investment in vaccine development is lagging, report finds

hotspot

Wikipedia

WSS

Readout Newsletter: CG Oncology IPO, Eli Lilly, Tesla, Merck

Investment in vaccine development is lagging, report finds

Kenai launches with $82 million for Parkinson’s stem cell therapy

RSV vaccines may be linked to small increased risk of developing GBS

House looks to weaken Medicare negotiation

Humana’s losses in Medicare Advantage tank its stock

explore

hotspot

hotspot

Continuity nursing helped my family in our darkest PICU moments

FDA does about

Medical leaders decry Supreme Court decision on affirmative action

Vertex non

How to save PrEP access — and even expand it

In search for therapies for solid tumors, companies turn to claudin

Walensky prepares to leave CDC — and Congress — behind

Kristina Burow of ARCH Venture Partners shares her next big bets STAT

Bright Health sells Medicare Advantage business to Molina

Investment in vaccine development is lagging, report finds

entertainment

An inside look at PIPEs, biotech's buzzy new financing tool

Bernie Sanders is gearing up to subpoena pharma CEOs

New clues to why women have higher risk of autoimmune disorders

Pfizer highlights cancer drugs it thinks could reignite investor interest

Readout Newsletter: The latest on Novavax, Merck, Bluebird

Biogen walks away from Aduhelm, years after polarizing approval

focus

hotspot

Wikipedia

focus